Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL ISIN · CA57384M1077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2024-07-24 Regulatory Filings
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the extension of a collaboration for pre-clinical testing of a drug candidate (MB204) for Rett syndrome. It contains no financial data, no regulatory form references, no voting results, no management or board changes, no earnings or financial statements, and no mention of any report publication. The content is primarily a corporate announcement about research and development progress and collaboration extension. This type of document fits best under Regulatory Filings (RNS) as a general regulatory announcement or corporate news release that does not fit into more specific categories.
2024-07-24 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a news release announcing an update on a private placement offering by Marvel Biosciences Corp. It references the TSX Venture Exchange's conditional acceptance and an extension for filing final documentation. The content focuses on financing activity and does not contain financial statements or detailed financial analysis. The document length is 3476 characters, which is relatively short and typical for an announcement rather than a full report. There is no indication that this is a full financial report, audit, or regulatory filing. The primary subject is the update on a private placement financing, which fits the Capital/Financing Update category.
2024-06-21 English
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a news release announcing a private placement financing by Marvel Biosciences Corp. It details the terms of the offering, including the number of units, pricing, warrants, use of proceeds, and conditions such as hold periods and regulatory acceptance. There is no financial statement or detailed financial report included, only an announcement of a capital raising event. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes.
2024-05-17 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CFO of Marvel Biosciences Corp. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2024. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3017 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2024-03-26 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CEO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2024. It is a certification letter rather than the interim report itself. The document length is short (3038 characters) and it primarily contains officer certification statements without substantive financial data or analysis. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself.
2024-03-26 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) for the six months ended January 31, 2024. It references unaudited condensed interim consolidated financial statements for the six months ended January 31, 2024 and 2023, and audited consolidated financial statements for the year ended July 31, 2023. The content includes detailed discussion of business strategy, product development, forward-looking statements, and financial reporting standards (IFRS). The length is substantial (15,000 characters), and the document contains substantive financial and operational analysis rather than just an announcement or certification. This fits the definition of an Interim / Quarterly Report (IR), which includes comprehensive financial reports for periods shorter than a full fiscal year with actual financial data and analysis. Therefore, the correct classification is IR with high confidence.
2024-03-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.